MedTrace Logo

Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle

NCT04880681 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-01

No results posted yet for this study

Summary

Patient-blinded randomized controlled trial evaluating length and quality of prostate biopsies taken by a novel biopsy needle.

Conditions

  • Prostate Cancer (Diagnosis)

Interventions

DEVICE

Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.

Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.

DEVICE

Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)

Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Adam Linder, Ass prof · Lund University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2023-12-30
Completion
2024-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04880681 on ClinicalTrials.gov